image
Healthcare - Medical - Equipment & Services - NYSE - US
$ 15.29
-1.23 %
$ 2.63 B
Market Cap
-2.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVST stock under the worst case scenario is HIDDEN Compared to the current market price of 15.3 USD, Envista Holdings Corp is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVST stock under the base case scenario is HIDDEN Compared to the current market price of 15.3 USD, Envista Holdings Corp is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one NVST stock under the best case scenario is HIDDEN Compared to the current market price of 15.3 USD, Envista Holdings Corp is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NVST

image
$23.0$23.0$22.0$22.0$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
2.51 B REVENUE
-2.18%
-1.04 B OPERATING INCOME
-3295.87%
-1.12 B NET INCOME
-1016.37%
336 M OPERATING CASH FLOW
22.05%
-54.6 M INVESTING CASH FLOW
12.50%
-104 M FINANCING CASH FLOW
-87.22%
653 M REVENUE
8.64%
46.1 M OPERATING INCOME
120.57%
1.2 M NET INCOME
-85.37%
132 M OPERATING CASH FLOW
87.27%
-7.4 M INVESTING CASH FLOW
75.82%
-900 K FINANCING CASH FLOW
99.10%
Balance Sheet Envista Holdings Corp
image
Current Assets 1.79 B
Cash & Short-Term Investments 1.07 B
Receivables 363 M
Other Current Assets 356 M
Non-Current Assets 3.56 B
Long-Term Investments 0
PP&E 420 M
Other Non-Current Assets 3.14 B
19.98 %6.78 %6.66 %7.85 %58.73 %Total Assets$5.4b
Current Liabilities 879 M
Accounts Payable 175 M
Short-Term Debt 150 M
Other Current Liabilities 554 M
Non-Current Liabilities 1.54 B
Long-Term Debt 1.4 B
Other Non-Current Liabilities 140 M
7.23 %6.23 %22.92 %57.84 %5.79 %Total Liabilities$2.4b
EFFICIENCY
Earnings Waterfall Envista Holdings Corp
image
Revenue 2.51 B
Cost Of Revenue 1.14 B
Gross Profit 1.37 B
Operating Expenses 2.41 B
Operating Income -1.04 B
Other Expenses 80.4 M
Net Income -1.12 B
3b3b3b3b2b2b2b2b1b1b500m500m00(500m)(500m)(1b)(1b)(1b)(1b)3b(1b)1b(2b)(1b)(80m)(1b)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
54.68% GROSS MARGIN
54.68%
-41.35% OPERATING MARGIN
-41.35%
-44.56% NET MARGIN
-44.56%
-38.12% ROE
-38.12%
-20.91% ROA
-20.91%
-23.16% ROIC
-23.16%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Envista Holdings Corp
image
400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -1.12 B
Depreciation & Amortization 40.8 M
Capital Expenditures -33.8 M
Stock-Based Compensation 35.3 M
Change in Working Capital 0
Others 1.46 B
Free Cash Flow 303 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Envista Holdings Corp
image
Wall Street analysts predict an average 1-year price target for NVST of $19.8 , with forecasts ranging from a low of $17 to a high of $23 .
NVST Lowest Price Target Wall Street Target
17 USD 11.18%
NVST Average Price Target Wall Street Target
19.8 USD 29.62%
NVST Highest Price Target Wall Street Target
23 USD 50.43%
Price
Max Price Target
Min Price Target
Average Price Target
232322222121202019191818171716161515May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Envista Holdings Corp
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
907 K USD 2
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Dental Burs Market Trends Analysis Report 2025-2030, with Profiles of Dentsply Sirona, Coltene, Shofu, MANI, Brasseler USA, American Orthodontics, Prima Dental, Diatech, Komet Dental & Envista Dublin, March 14, 2025 (GLOBE NEWSWIRE) -- The "Dental Burs Market Size, Share & Trends Analysis Report by Material (Diamond Burs, Stainless Steel, Carbide), Application (Oral Surgery, Implantology, Orthodontics), End-Use (Hospitals, Dental Clinics), and Region with Growth Forecasts, 2025-2030" report has been added to ResearchAndMarkets.com's offering. The Dental Burs Market was valued at USD 640.1 million in 2024, and is projected to reach USD 881.6 million by 2030, rising at a CAGR of 5.50%. The increasing prevalence of oral conditions in developed and developing countries is expected to propel the market's growth. Moreover, the growing accessibility of oral care in developing countries owing to the awareness campaigns and initiatives is expected to contribute to the market growth over the forecast period. For instance, the Oral Health Foundation is celebrating National Smile Month from 15 May to 15 June 2023 to raise awareness regarding oral health conditions globally. Dental caries or tooth decay is the most prevalent oral health condition and remains untreated. These oral health conditions can be treated with non-invasive methods if identified early. According to the FDI World Dental Federation, around 3.5 billion individuals globally suffered from oral diseases in 2020, and around 2.3 billion individuals were estimated to suffer from tooth decay in 2020. The high prevalence of tooth decay can be due to the factors such as changing lifestyles, high sugar consumption, and less awareness about oral hygiene in low- and middle-income countries. Hence, the demand for dental procedures is rising with the increasing prevalence of oral conditions in the geriatric population globally. According to the article published in PubMed Central in March 2022, the prevalence of tooth decay in the geriatric population was around 49% globally. Periodontal disease, root caries, and xerostomia are oral diseases that primarily affect the elderly population. Even though these conditions affecting the geriatric population are preventable or treatable, many do not receive the necessary treatment. Dental Burs Market Report Highlights globenewswire.com - 1 month ago
Why Is Envista (NVST) Down 18.2% Since Last Earnings Report? Envista (NVST) reported earnings 30 days ago. What's next for the stock? zacks.com - 1 month ago
Reasons to Retain Envista Stock in Your Portfolio for Now NVST's impressive long-term growth initiatives appear promising. Yet, a leveraged balance sheet is worrisome. zacks.com - 1 month ago
Envista Smile Project Donates $1.8 Million in 2024 BREA, Calif. , Feb. 25, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") proudly announced that in 2024, the Envista Smile Project (Smile Project) contributed $1.8 million to further its mission of enhancing oral health accessibility for underserved communities. prnewswire.com - 1 month ago
NVST Stock Up on Q4 Earnings and Revenue Beat, Operating Margin Crashes Envista delivers better-than-expected top and bottom-line results for the fourth quarter of 2024. zacks.com - 2 months ago
Envista Holdings Corporation (NVST) Q4 2024 Earnings Call Transcript Envista Holdings Corporation (NYSE:NVST ) Q4 2024 Earnings Conference Call February 5, 2025 5:30 PM ET Company Participants Jim Gustafson – Vice President-Investor Relations Paul Keel – President and Chief Executive Officer Eric Hammes – Chief Financial Officer Conference Call Participants Elizabeth Anderson – Evercore ISI Jon Block – Stifel Ahmed Muhammad – Leerink Partners Jeff Johnson – Baird Kevin Caliendo – UBS Erin Wright – Morgan Stanley Steven Valiquette – Mizuho Securities Brandon Vazquez – William Blair Vik Chopra – Wells Fargo Operator Hello. My name is David, and I'll be your conference call facilitator this afternoon. seekingalpha.com - 2 months ago
Here's What Key Metrics Tell Us About Envista (NVST) Q4 Earnings While the top- and bottom-line numbers for Envista (NVST) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 months ago
Envista (NVST) Beats Q4 Earnings and Revenue Estimates Envista (NVST) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.29 per share a year ago. zacks.com - 2 months ago
Envista Reports Fourth Quarter 2024 Results BREA, Calif. , Feb. 5, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended December 31, 2024. prnewswire.com - 2 months ago
Envista to hold Capital Markets Day on March 5, 2025 BREA, Calif. , Feb. 4, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will hold a Capital Markets Day on Wednesday, March 5, from 9:00 a.m. prnewswire.com - 2 months ago
Envista (NVST) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 months ago
Update: Envista Schedules Fourth Quarter 2024 Earnings Call BREA, Calif. , Jan. 27, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025. prnewswire.com - 2 months ago
8. Profile Summary

Envista Holdings Corp NVST

image
COUNTRY US
INDUSTRY Medical - Equipment & Services
MARKET CAP $ 2.63 B
Dividend Yield 0.00%
Description Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
Contact 200 S Kraemer Blvd Bldg E, Brea, CA, 92821-6208 http://www.envistaco.com/
IPO Date Sept. 18, 2019
Employees 12300
Officers Mr. Faez Kaabi Vice President, Chief Accounting Officer & Corporate Controller Mr. Filippo Impieri Senior Vice President of Emerging Markets Mr. Eric D. Hammes Chief Financial Officer Mr. Mischa M. Reis Senior Vice President of Strategy & Corporate Development Mr. Andrew Chen Chief Information Officer Mr. Stephen Keller Vice President of Investor Relations Mr. Suraj Satpathy Chief Human Resources officer Mr. Mark E. Nance J.D. Senior Vice President, General Counsel & Secretary Mr. Paul A. Keel Chief Executive Officer & Director Paul Sumilas Chief Compliance Officer